INDEPENDENT STUDY OF OVARIAN CANCER CTCS HARVESTED BY THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO PREDICT PROGRESSION FREE SURVIVAL FOR DRUG TRIALS The study investigated 123 metastatic ovarian ...
Parsortix platform shown to be compatible with the Roche BenchMark ULTRA automated staining system, with initial study of three key drug targets: HER2 (breast), TROP2 (lung) and PSMA (prostate) Roche ...
Development of both the prostate cancer androgen receptor assay and the multi-cancer DDR micronuclei assay successfully completed for AstraZeneca Results of Eisai Phase 2 pilot study supports the ...
Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients LONDON and NEW YORK, November 06, 2008 /PRNewswire/ -- Morria ...
ABINGDON, OXFORDSHIRE / ACCESSWIRE / November 14, 2022 / Midatech Pharma PLC (AIM:MTPH.L; Nasdaq:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of ...
DUBLIN, April 1, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to ...
We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a look at where Medtronic plc (NYSE:MDT) stands against the other medical AI ...
* Strongbridge Biopharma Plc - phase 3 sonics study is now more than 80 percent enrolled and we remain on track to fully enroll study during Q2 * Strongbridge Biopharma Plc - on schedule to commence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results